ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

Genomic Intelligence and Resistance Evolution: Redefining Oncotherapeutic Strategies in Precision Oncology

Dr. Muchukota Sushma[1]; Bharathi Bhogenahalli Venkatappa[2]*; Gowthami V.[3]; Nigel Viju Thomas[4]; Souman Samanta[5]

[1]Associate Professor, [3]4th Pharm D Student, [2, 4,5] 5th Pharm D Students

[1,4,5]Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore.
[3]Department of Pharmacy Practice, Al-Ameen College of Pharmacy, Bangalore.
[2]Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Kogilu Cross, Yelahanka, Bangalore-64, India.

Corresponding Author: Bharathi Bhogenahalli Venkatappa[2]*

Publication Date: 2025/08/28

Abstract: The discovery of genomics has redefined oncology into precision rather than standardized treatment. But therapeutic resistance of either kind, intrinsic or acquired, is a serious impediment to sustained success. The present review outlines the domains on the crossroad between genomic intelligence and resistance evolution, where multi-omics profiling, high-throughput sequencing, and AI-based analytics are explaining the challenging complexity of the tumor and predicting resistance pathways. We review the contribution of clonal evolution, tumor plasticity and adaptive signaling in resistance to therapy, and we promote moving towards active molecular monitoring rather than snapshot ting genome. To preempt and target therapeutic escape we suggest a framework of adaptive precision oncology that comprehends real-time biomarkers, liquid biopsy follow-up and resistance-predictive algorithms. New approaches like combination therapy, recalibration of treatment with the help of AI, and longitudinal monitoring of genomes are mentioned. We also deal with moral and logistical obstacles of adopting these strategies, and especially in low-resource environments. The new era of precision oncology We now find ourselves in the next era of precision oncology that aims to personalization extend to real-time responsiveness, so that cancer treatment can increasingly be more adaptable, more resilient and more durable, achieved through personalizing the rapidly changing tumor biology with real-time dynamically changing genomic insights.

Keywords: *Precision Oncology, Genomic Intelligence, Therapeutic Resistance, Adaptive Therapy, Liquid Biopsy, Tumor Heterogeneity.*

How to Cite: Dr. Muchukota Sushma; Bharathi Bhogenahalli Venkatappa; Gowthami V.; Nigel Viju Thomas; Souman Samanta (2025) Genomic Intelligence and Resistance Evolution: Redefining Oncotherapeutic Strategies in Precision Oncology. *International Journal of Innovative Science and Research Technology*, 10(8), 1425-1435. https://doi.org/10.38124/ijisrt/25aug886

I. INTRODUCTION

Cancer, of which used to be chaotic and heterogeneous disease, now is more and more explained by the genomic and molecular approach to it.[(1)] Since we have appreciated an understanding that cancer being, at its basis, a disease of the genome is developed through somatic mutation and chromosomal rearrangement and given control over by epigenetics, then the concept behind the treatment takes the shape of precision-based treatment rather than that of trial and error and as is otherwise costly and time-consuming.[(2)] With the development of precision oncology supported by next-generation sequencing (NGS), it has been possible to match therapies with given oncogenic drivers in subsets of cancers including BCR-ABL1-positive chronic myeloid leukemia (CML) and epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).[(3)] However, even despite them, there is one formidable and almost universal challenge: the therapeutic resistance.

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

In history, the methods of treating people with cancer e.g. radiation and chemotherapy were crude tools they worked but in a non-selective way.[4] A new class of more focused treatments based on targeted therapies of all kinds was a step toward a more rational, genotype-driven intervention. Cancers however, change.[5] Resistance may be inherent in the baseline molecular design of the tumor or acquired by de facto evolution in response to the pressure of therapy.[6] The controls of these mechanisms of resistance are intra tumoral heterogeneity, clonal evolution, plasticity phenotypes and the remodeling of the microenvironment.[7]

In this regard, the disadvantage of the static molecular profiling is made evident. One biopsy will tell only the state of a tumor at a particular moment of time, not predict its evolution.[8] At this point the paradigm of genomic intelligence becomes revolutionary. Genomic intelligence is described as the dynamic contextual analysis of multi-dimensional molecular data interacted with clinical, phenotypic and environmental factors in order to inform therapeutic decision-making in real-time.[9] It is more than mutation detection, and includes AI-based analytics, systems biology and combinations of multi-omics to predict tumor evolution and resistance.[10]

The central change here is a redefinition of the term precision. When precision was identified with determination of actionable mutations, today it will demand longitudinal, temporal insight on genomics and resistance development.[11] It is possible to anticipate the adaptation of tumors and keep them at bay with the help of such emerging technologies as liquid biopsies, single-cell sequencing, spatial transcriptomics, and AI-driven resistance prediction. It marks a transition into a new way of doing things, anticipatory oncology, a proactive form of care that not only treats the tumor as it is, but as it is likely to be.[12]

This review focuses on combining both genomic intelligence and resistance evolution to help provide oncotherapeutic approaches in a new generation of oncotherapeutics. Our analysis of forces then proceeds to the postcripts as the decoding of resistance trajectories through NGS, multi-omics and machine learning.[13] Biological modalities of therapeutic escape are then discussed, such as genetic reprogramming, epigenetic adjustment, and micro environmental plasticity.[14]Applicable examples will be supplied, such as liquid biopsy monitoring and adaptive therapy schemes, which will be presented in the actual situations.[15]

- *Genomic Intelligence: Foundations, Technologies, and Translational Potential*

Genomic intelligence is a job that goes beyond conventional DNA sequencing- it is an agile capability to obtain, combine, prevision, and present molecular information on the cancer genome in clinical practice in real time. With the migration of precision oncology beyond phenotyping of cancer genomes towards evolution-aware, even adaptive, therapeutic approaches, however, genomic intelligence comes to the fore as the pivotal engine that will drive proactive, personalized cancer treatments.[16]

The origin of genomic intelligence starts where the data is obtained but its definition lies in the ability to interpret. High-throughput sequencing produces huge amounts of data including somatic mutations, gene fusions, copy number changes, transcriptomic changes, and epigenetic signature.[17] The valuable part in the transformative data is not raw data but the contextual interpretation of those data- annotation of variants driver, versus passenger mutations, and mappings to curated oncogenic knowledge bases, including OncoKB, COSMIC, and ClinVar. [18]

The intelligence is a collaboration of many interests at the crossroad of bioinformatics, system biology, clinical oncology, where molecular portrait is combined with phenotypic behavior and treatment index, and clinically based context. Knowing that a mutation exists, not only is required, but it is essential to predict what this mutation will do with therapeutic pressure, and how it will vary in time and space (anatomical compartment).[19] **Figure1** demonstrates how a frame sequential system works to convert real-time genomic intelligence to patient sample, sequencing, bioinformatics analysis, and interpretation followed by adaptive treatment recommendations as part of an ongoing feedback loop.



Fig 1 Real -Time Genomic Intelligence Workflow

Genomic intelligence is driven by an advanced combining of technologies which use molecular information to produce the useable discoveries. Next-generation sequencing (NGS) Knowledge of the driving mutations and low frequency variants can also be done using next-generation sequencing (NGS) platforms, including WGS, WES, and targeted panels. Intratumoral heterogeneity and resistant clones of the tumor microenvironment are deciphered with the help of single-cell and spatial transcriptomics.[20] The combined omic of transcriptomic, proteomic, metabolomic, and epigenomic provides

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

information on how the pathway is rewired going beyond the genomic variations. Central to these insights are artificial intelligence (AI), in which predictions of treatment response are made using machine learning models that are trained using large-scale datasets, to simulate resistance evolution, and identify synergistic targets to drug combinations. A combination of the technologies can convert inert molecular signatures into dynamic, evolution-sensitive systems to inform mindful cancer therapy.[21] One CDx, already affect therapeutic decision-making in clinics. As part of the larger field of explainable AI, application of interpretable AI (e.g., explain ability through SHAP values) into clinical platforms and systems is also on the rise to improve transparency, and therefore clinician acceptance.[22]

Genomic intelligence has passed into research and is now being transferred into ordinary practice. Molecular tumor boards, genotype-guided clinical decision support systems (CDSS) and N-of-1 precision trials are being incorporated at academic and tertiary institutions. Clinician-friendly platforms such as cBioPortal and My Cancer Genome enable clinicians to put genomic variation in perspectives provided by drug responsiveness, drug trial eligibility, and drug-resistance predictive factors.[23]

Some institutions have incorporated molecular profiling into regular practice operations at Memorial Sloan Kettering, MD Anderson, and Dana-Farber, not simply to guide initial choice of therapy but also to monitor resistance in real time. National efforts such as NCI-MATCH, PREDICT, and NCI-MPACT represent the building interest in adaptive, genotype-driven trial design.[24] The emerging genomic intelligence is based on enabling technologies as illustrated in **table 1** which includes high throughput sequencing platforms, bioinformatic pipelines, AI-informed analytics, cloud-based genomic storage and integrative multi- omics structures that enable the conversion of raw genomic data to translate into therapeutic potential.[25]

Table 1 Foundational Technologies Enabling Genomic Intelligence

Technology	Description	Application	Relevance to Resistance
NGS	High-throughput DNA sequencing	Mutation profiling	Detect low-frequency resistant clones
Sc RNA-seq	Single-cell RNA sequencing	Cellular heterogeneity	Identify drug-tolerant persisters
Spatial Transcriptomics	Gene expression in tissue context	TME mapping	Locate resistance niches
Multi-Omics	Integrated omics analysis	Pathway mapping	Uncover bypass and compensatory signaling

II. RESISTANCE EVOLUTION IN CANCER

➢ *Biological Mechanisms and Clinical Implications*

As accurate as current cancer treatments have become, there can be no question of resistance in advanced malignancies being an eventuality; indeed, one might even pay accolade to the excellence of cancer as one of the most evolutionarily adaptive diseases in the world.[26] Resistance can be intrinsic and present at baseline as a result of prior mutation (e.g. undermining of EGFR blockade by KRAS mutation or blunting of PI3K response by PTEN loss), or acquired caused by Darwinian selection in favor of resistance sub clones under selection pressure.[27] Mechanistically, resistance can occur in various pathways: secondary mutation (e.g. EGFR T790M, ABL1 T315I), bypass signaling along alternative pathways (e.g. MET, HER2 or HER amplification), phenotypic plasticity including epithelial-to-mesenchymal transition (EMT) or histological trans differentiation states as well as epigenetic reprogramming to promote drug tolerant persisted states.[28]

Tumor micro environment also regulates resistance through stoma candor, hypoxia and immune evasion, such as loss of neoantigens or MHC down regulation.[29] Of importance in these processes are the clonal evolution in which treatment of the disrupts the sensitive clones, leaving room for the growth of resistant populations in a nonlinear and dynamic way. This is complicated by tumor heterogeneity both spatial and temporal; when taken singly; individual time-point biopsies are ineffective.[30]New evidence is backing up such resistance delaying strategies as adaptive dosing, multi-site profiling and clonal surveillance. But to get to the point where therapeutic resilience is truly a reality, real-time genomic intelligence that can predict, track, and counter resistance before it happens will be needed to bring oncology into the age of anticipatory interceptions rather than reactivity rescue.[31] **Table 2** provides the complete picture of molecular resistance mechanisms identified among the primary cancer types with the following alterations in drug targets, the activation of compensatory signaling pathways, epithelial-mesenchymal transition (EMT), overexpression of efflux transporters, and modulation of a tumor microenvironment shown to contribute to failure and emphasizing the role of genomic-driven approaches to overcome resistance.[32] **Figure 2** shows varied resistance mechanisms of precision oncology, such as genetic mutations, pathway reactivation, phenotypic plasticity, and microenvironmental and adaptive cellular resistance to the therapy.

Table 2 Resistance Mechanisms in Major Cancers

Cancer Type	Targeted Therapy	Resistance Mechanism	Clinical Implication
NSCLC	EGFR inhibitors	T790M mutation	Switch to Osimertinib
Breast Cancer	Endocrine therapy	ESR1 mutations	Use SERDs or switch to CDK4/6 inhibitors
Colorectal Cancer	Anti-EGFR therapy	KRAS mutations	Discontinue EGFR blockade
CML	Imatinib	T315I mutation	Use ponatinib

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886



Fig 2 Mechanisms of Resistance in Precision Oncology

➢ *Liquid Biopsy and Dynamic Genomic Surveillance: Tracking Tumor Evolution in Real Time*

Cancer is dynamic as it evolves under the pressure of therapy, and therefore classical biopsies cannot fully characterize the molecular complexity of cancer. Liquid biopsy has become a paradigm shifting, low-intervention method of real-time monitoring of tumor evolution and resistance.[33] The surveillance of circulating tumor DNA (ctDNA), circulating tumor cells or CTCs (extracellular vesicles) and noncoding RNs in the blood allows clinicians to perform noninvasive detection of emerging mutations, follow minimal residual disease (MRD), and monitoring of clonal dynamics during treatment.[34] Out of those ctDNA has received the most clinical interest as they are specific and can echo systemic tumor heterogeneity. Examples of applications include early prediction of resistances mutations (e.g. EGFR T790M, KRAS, ESR1) to predict relapse by detecting minimal residual disease and adaptive complementary therapy based on real-time clonal dynamics.[35] Its use as a predictor of therapeutic escape prior to clinical development has been confirmed by such landmark trials as AURA3 and TRACERx. Using AI, liquid biopsy data can now be used to predict resistance trajectories, simulate the evolution of tumors and recommend therapy changes, all in a framework of genomic intelligence.[36] Although issues like sensitivity inconsistency, platform variations and interpretative limitations affect its accuracy, its accuracy is still being boosted by the emerging technologies in ultra-deep sequencing, fragmentomics and multi-analyte assays. Finally, liquid biopsy is being transformed to a proactive molecular guide through the shifting terrain of resistance that has emerged in precision cancer medicine.[37]

➢ *AI-Driven Modeling of Resistance Pathways and Predictive Therapeutics*

Since cancer treatment is becoming highly personalized, the ability to handle resistance becomes one that is computationally sophisticated rather than a medical judgment. Increasingly, artificial intelligence (AI), combined with machine learning (ML) and systems biology, is becoming the main paradigm to model resistance evolution, forecast the response to treatment and the time course of treatment sequences.[38] With AI, the frozen genomic data turns dynamic into a narrative of the future- when, how and where the resistance is bound to take place. Approaches, such as supervised and unsupervised learning, deep learning, or reinforcement learning allow real-time simulation of clonal dynamics, the search of synthetic lethal targets, and smart adjustment of therapy.[39] Uses include virtual tumor twins to model paths of treatment, to drug repurposing engines to find novel resistance modifiers that were not obvious. In healthcare, decision support systems (CDSS) based on AI are already in use, including Watson for Genomics and Tempus as clinical tools that combine genomic data with knowledge bases to produce context-sensitive recommendations of therapeutic actions.[40] Nevertheless, there are still problems, such as black-box algorithms, data-bias, and ethics reduce interpretability and trust of them. The next development of AI application in precision oncology is an evolution-competent, dynamic treatment platform capable of continuous training by real-life data that ensures a specific approach to prevent the emergence of resistance in individuals and or even before resistance occurs. **Table 3** provides an overview of the varied AI-enabled tool and application in medico genomics, including machine learning variant interpretation tools, natural language processing for clinical annotation, deep learning drug response prediction tools and end-to-end AI-powered AI platforms that allow providing personalized medication recommendations based on genomic, phenotypic, and pharmacological data integration.[41]

Table 3 AI Tools and Applications in Medicogenomics

AI Tool	Application Area	Use Case Example
IBM Watson for Genomics	Genomic interpretation	Matches genomic alterations with therapies
Tempus	Data-Driven treatment planning	Combines clinical, molecular, and outcomes data
Paige AI	Histopathology analysis	Uses deep learning for pathology image recognition
Path AI	Biomarker detection	Correlates histology with genomic mutations
Deep variant	Variant calling	High-accuracy detection of SNPs and indels

➢ *Therapeutic Adaptation: Rethinking the Design of Cancer Therapies in the Resistance Era*

Static precision oncology, which aims at matching drugs to actionable mutations, is lame against dynamic resistance evolution. The future is resistance-conscious therapies in which treatment incurs a genomic definition, driven by real-time genomic intelligence, adaptive, and anticipatory. The need to beat the monotherapy limits is driving the need to rationally combine agents based on resistance pathway modulated by vertical inhibition of signaling cascades (e.g., BRAF + MEK), or horizontal blockade of rescue signals (e.g., EGFR + MET). In addition

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

to combinations, targeting synthetic lethality and collateral sensitivity presents new therapeutic turns as the tumors change.[42]The time aspect in therapeutics is also of critical importance; adaptive scheduling, evolutionary-based dosing (based on biomarkers such as ctDNA) has held promise as a way to delay resistance and extend response. Attacking tumor plasticity and drug tolerant persister states using epigenetic or metabolic weaknesses as a target brings an additional reversibility dimension to resistance control.[43]Notably, pharmacogenomics will improve drug selection and ordering by disclosing risk of drug resistance through metabolism and transporter basis. The second horizon is resistance-adaptive clinical trials- baskets, umbrella and platform trials, which adjust therapy in real time in response to new genomic information arising.[44] Today, in this paradigm, treatment was not a one-time instance that would include patients, but it would also evolve along with the tumor, the goal not only to have immediate response, but also sustainable and preemptive resistance inhibition. **Table 4** demonstrates examples of the therapeutic failure due to resistance to treatment in different malignancies and the interventions based on the genomic intelligence-mediated approaches that have facilitated the development of adaptive treatment methods, biomarker-informed drug choice, and re-sensitization strategies to overcome resistance to therapy.[45]

Table 4 Examples of Resistance-Driven Therapy Failures and Genomic Intelligence-Based Interventions

Cancer type	Therapy	Resistance Mechanism	Genomic Solution	Outcome
NSCLC	EGFR-TKI	T790M mutation	Osimertinib	Extended PFS
Melanoma	BRAF inhibitor	MAPK reactivation	Pathway combination inhibitors	MEK/BRAF reduced resistance

- *Tumor Microenvironment and Immunogenomic Interactions in Resistance Evolution*

This Tumor Micro Environment (TME), itself a dynamic co-evolved ecosystem, consists of immune infiltrates, stromal cells, extracellular matrix (ECM), vasculature and a mesh of soluble factors. Conversely to being a passive scaffold, TME has a participatory role in defining tumor behaviors, responsiveness to treatment, and more importantly resistance evolution. Growing data point to the conclusion that resistance is not merely a cell-intrinsic genomic event but is highly embedded into extrinsic ecological forces inside the TME. In that regard, the formulation of the response to resistance ought to be a systems-level response that considers the interaction between the tumor cells and their immediate environment.[46]

The adaptive immune evasion is one of the peculiarities of the mechanisms that tumors evolve during immunotherapeutic pressure. Loss of neoantigen expression, MHC class I down regulation and JAK1/2 mutations are some of the mechanisms that hinder to interferon signaling and dulls T-cell recognition. These adaptations reflect the patterns of resistance during targeted therapies in cancers such as melanoma proving that evolution of resistance occurs not only in the genomic scale but also in immunologic scales. In addition, cancerous cells may activate immune checkpoint receptors detecting a high level of PD-L1 to activate the cancer cells and inhibit the killing activities of cytotoxic T-cells, which is frequently done once the cancer cells, are attacked by the immune system.[47]

The relationship between genomic alterations and TME is a two-way communication which induces immune resistance. Mutations that contribute to cancer such as KRAS, PTEN loss, and WNT/beta- catenin stimulation are able to establish an immunosuppressive or immune- excluded environment dissimilitude suppressing cells; altering cytokine landscapes, or sequestering T cells out of the tumor center. These genotype phenotype differences lead to the development of immunological deserts where even effective immunotherapies cannot work, owing to the absence of immune stimulation at the site of disease.[48]

Physical barriers Stromal barriers, especially cancer-associated fibroblasts (CAFs) and ECM components, are physical barriers to drug access and immunologic access. In desmoplastic cancer, such as that in pancreatic ductal adenocarcinoma, hypoxia and acidic niches created by dense fibrotic matrices in a tumor protect drug-resistant clones.[49] CAFs may also release pro-survival molecules (e.g., HGF) and this upregulates bypass pathways via activation of bypass proteins (example, activation of MET pathway) resulting in the escape of the cancer cells in response to EGFR-targeted therapies. A logical next step is to modulate the TME with stromal-depleting agents, TGF-β inhibitors, or anti-angiogenic therapy as a method to increase the ability to penetrate in the treatment and slow the emergence of resistance.[50]

New immunogenomic biomarkers are possible to observe the development of resistance over time in real-time. It is possible to look at the immune dynamics and tumor escape mechanism using tools to monitor the dynamics of T-cell receptor (TCR) diversity, neoantigen load, and HLA loss of heterozygosity (LOH). These proposed biomarkers are central to adaptive immunotherapy, in which therapy is dynamically targeted on the condition of the immune landscape, via such combination approaches as bispecific antibodies or checkpoint modulation. [51]

The tumor and gut microbiome is another unexpected frontier in resistance evolution as evidenced by its effects on immune tone and response to therapy. The microbiota variation was implicated in the reduced efficiency of the PD-1 blockade and antibiotic usage in early failure of immunotherapy. Probiotics/fecal microbiota transplant (FMT)/dietary attempts at modulating the microbiome can provide a new knob to turn to weight the balance of the immune system towards treatment sensitivity.[52]

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

➢ *Pharmacogenomics-Driven Therapy Optimization*

Pharmacogenomics (PGx) is imperative in the maximization of cancer treatment especially where there is emerging resistance. There is genomic polymorphism of drug-metabolizing enzymes (e.g. CYP2D6, DPYD, and UGT1A1), transporters (ABCB1), and pharmacodynamic targets in both therapeutic efficacy and toxicity that determine resistance patterns.[53] To give an example, poor metabolizers of CYP2D6 are less active in tamoxifen activation and risk endocrine resistance, and DPYD/UTG1A1 variants affect the tolerance of fluoropyrimidines and Irinotecan, and individual doses can be personalized. Alongside the main treatment, PGx can inform flexibly adaptive therapy, e.g. with progression of a non-small cell lung cancer, sequencing EGFR TKIs based on resistance mutations (e.g. T790M, C797S) or re-challenge with drugs during drug holiday.[54] The clinical decision support systems (CDSS) powered by AI, and combining PGx landscape, tumor genomics, and real-time liquid biopsies currently allow the dynamic alteration of therapy. Notwithstanding the limitations of access, clinician literacy, and standardization, the integration of the fields of PGx and genomic surveillance and AI modeling provides an effective path regarding overcoming resistance, individualizing dose prescription, and prolonging treatment response to the era of precision oncology.[55]

➢ *Pharmacogenomics-Driven Therapy Optimization and Real-World Case Evidence*

Case examples that involve real-life situations highlight the translational effects of the genomic intelligence in the journey of defeating resistance. Most patients with EGFR-mutant non-small cell lung cancer (NSCLC) who used first-generation TKIs (e.g., erlotinib) subsequently acquire T790M-level resistance; this was meaningfully reversed with Osimertinib, as seen in the AURA3 study, which was designed with ctDNA used as a prompt to switch patients early. In the case of colorectal cancer that has spread, usually to the liver, patients initially sensitive to the anti-EGFR antibodies (cetuximab/panitumumab) develop resistance to therapy consequent to emergent KRAS mutations that can be detected by means of liquid biopsy; tactical drug holidays followed by re-challenge to anti-EGFR has been used to re-sensitize the tumors as seen in the CRICKET trial and the CHRONOS trial.[56] Another example is hormone receptor-positive breast cancer: ESR1 mutations, acquired during treatment with aromatase inhibitors, suggest resistance and are now applied to direct the switch of treatment regimen to selective estrogen receptor degraders (e.g., elacestrant which was validated in EMERALD trial). PARP inhibitors in BRCA-mutated tumours have already demonstrated synthetic lethality, but resistance by BRCA reversion mutation or fork protection is proliferating being dealt with by ATR or WEE1 inhibitors, already in clinical trial such as CAPRI and VIOLETTE. These illustrations point to the realization that real-time genomic monitoring and pharmacogenomic adaptation hold the potential to inform drug selection, shift timing, and rechallenge, as they promise to usher in the evolution-aware model of oncology.[57]

➢ *Real-Time Resistance Monitoring: Liquid Biopsy, AI, and Predictive Modeling*

Among the most monumental changes in the field of precision oncology, triggering a revolution, stands the genomic testing transition that left the stagnant, once-off analysis to the real-time monitoring of tumor evolution. With development of malignancies, resistance is almost inevitable due to adaptability according to pressure of therapy. To predict this development and therefore act early, it is useful to have tools; ones to track the molecular alterations in a non-invasive fashion over-time. The combined forces of liquid biopsy technologies and artificial intelligence (AI) and predictive modeling are making it possible to conduct proactive resistance monitoring prior to the manifestation of clinical progression.[58]

Liquid biopsies, especially circulating tumor DNA (ctDNA) are a less invasive source of detecting resistance mutations, monitoring the clonal evolution, and representing the heterogeneity of the tumor tissues. As an example, EGFR T790M mutations detected in ctDNA can be identified earlier than the radiological progression in non-small cell lung cancer (NSCLC), meaning that it is possible to switch to different therapy on time.[59] Likewise, progression of ESR1 mutation can be potentially detected using serial ctDNA of hormone receptor-positive breast cancer and mediate endocrine therapies. As opposed to the conventional biopsies, ctDNA ensures a pooling of the signal of all the metastatic tumors, and thus provides a systemic view of the tumor development. Such trials as TRACERx and PADA-1 have demonstrated the successful use of ctDNA as a predictively valued biomarker of resistance[60]

Resistance detection is also improved by means of artificial intelligence and digital pathology. AI has already learned how to analyze pathological slides and radiologic slides to speculate on molecular changes and forecast immune escape or transformation events.[61] Deep learning models also able to address ctDNA rich data, method artifacts removal and measure clonal burden. Resistance trajectories can be simulated using machine learning algorithms (e.g. Bayesian networks or dynamic survival models) using longitudinal multi-omics data and reveal early transformation events, such as a histologic change of NSCLC into small-cell lung cancer. [62]

Predictive modeling goes further and combines information on genomics changes, immune clones, treatment exposure, and clonal phylogenies in a bid to predict how and when resistance will occur. Such tools as PyClone and OncoNEM restore tumor development and recommend strategic treatment maneuvers. Adaptive modulation of treatment, so-called evolutionary steering, which aims to postpone resistance, is currently under trial.[63]

Decision support systems are important in clinical integration. Expert-assisted dashboards on or in electronic health records (EHRs) would in turn inform clinicians of new resistance markers and recommend evidence-based therapy adjustments. Regardless of certain problems, including sensitivity limits of ctDNA, or intricacy of interpretation,

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

real-time resistance monitoring holds a lot of potential. It enables the oncologists to identify relapse much sooner, customize the transitions between treatment, and anticipate resistance, transforming the field of oncology into a predictive and evolution-informed therapy system.[64]

- *Pharmacovigilance and Resistance Surveillance in Precision Oncology*

Pharmacovigilance in its new context in the changing environment of precision oncology, however, is no longer synonymous with monitoring of adverse drug reactions but has also evolved to the proactive monitoring of emergence of genomic resistance and drug safety in the real-world. Due to the growing popularity of targeted agents and use of immunotherapies and combination therapies, the patterns of resistance and toxicity are usually genotype-dependent, comorbidity-dependent, and treatment-history-dependent.[65]

Pharmacovigilance systems based on an AI, connect to electronic health records and real-time liquid biopsy data, can forecast emergence of early resistance signals, adverse events and drug-drug interactions specific to genomic subtypes. As an example, both development of resistance to EGFR in non-small-cell lung cancer or checkpoint in melanoma can be monitored along with pharmacogenomic profiles to predict and avoid discontinuation because of toxicity. Integration of these surveillance tools allow improved clinical outcomes and by extension it finds regulatory decision-making and post-marketing safety approaches.[66]

- *Strategies to Overcome and Prevent Therapeutic Resistance: Toward Durable Precision Responses*

Although it is crucial to characterize resistance mechanisms, the end result of precision oncology would be to avoid or circumvent resistance in order to achieve durable responses to therapy. Our rapidly improving understanding of tumor evolution is leading to a new surge in therapeutic approaches: adaptive, combinatorial and personalized approaches to cancer care.[67]

The focus of blockage of escape pathways is combination therapies. With tumors, the proliferation of redundant survival pathways makes the monotherapies useless. Dual combination (e.g. BRAF and MEK inhibitors in melanoma) therapy has demonstrated effectiveness in postponing the reactivation of the MAPK pathway. Horizontal targeting (e.g. PI3K and mTOR inhibitor) and vertical inhibition (e.g. EGFR & MET blockade in NSCLC) also inhibits compensatory signaling. Such trials as COMBI-d, BEACON CRC prove that combination strategies are more beneficial in progression-free survival and prevent resisting.[68]

The evolutionary ideas can be applied to the adaptive and sequential therapy, which is an alternative to continuous administration of a large dose of medicine. There can be a fitness cost to resistance it is in some cases to the advantage of a population to maintain drug-sensitive cells by intermittent dosing and, in this way, resistant clones will be suppressed by competition. To do so, this so-called tumor containment model (recently being tested in prostate cancer and NSCLC studies) involves making use of mathematical models and real-time biomarkers (e.g., ctDNA) to guide when to administer treatment and at what dosage.[69]

Immunotherapy combinations deal with immune evasion- one of the hallmarks of resistance. The tumors can abrogate antigen presentation (e.g., B2M mutations), or cooption of alternate checkpoints (e.g., TIM-3), or they can recruit immunosuppressive immune cells. A combination of checkpoint blockade with the targeted therapy or with epigenetic modifiers (e.g., HDAC inhibitors), or even oncolytic viruses, can re-program the immune environment, transforming the previously so-called cold tumors into responsive. Individualized combinations on the basis of the neoantigen load and signatures of T-cell infiltrations are arising.[70]

Synthetic lethality forms on the weak points of cancerous cells resistant to treatment. PARP inhibitors can be used in BRCA-deficient tumors, and ATR, CHK1 and WEE1 agents in p53-mutated or replication stressed tumors. CRISPR screen is still revealing novel single-synthetic lethal pairs in therapy-resistant clones.[71] The immune suppression and drug resistance is through progressive of CAFs, MDSCs, and hypoxic niches. To make the TME an ally, TGF-b, CXCR4, and VEGF inhibitors are under testing to remodel stroma, normalize vasculature, enhance delivery of drugs--all ways of turning a barrier into a helper.[72]

- *Future Directions toward a Self-Learning, Evolution-Resistant Precision Oncology Ecosystem*

The combination of the three technologies, genomics, artificial intelligence, and adaptive treatment paradigms, is the paradigm shift in oncology, namely, the shift towards dynamic, self-learning, and personalized cancer treatment. The adoptable inner sphere of this evolution is the concept of closed-loop learning system whereby all the information about each patient, including omics, imaging, and real-time liquid biopsy, becomes input to AI-powered models that make continuous improvement of therapeutic decisioning. The first attempts are represented by such platforms as PREDICT-PROACTIVE, Project GENIE, and Tempus, yet the end goal is real-time clinical feedback infusion to power real-time care adaption's.[73]

Predictive oncology is developing fast with machine learning approaches being able to predict clonal evolution, drug response dynamics, and suggest dynamic therapies ahead of the clinical emergence of resistance. The second frontier is the hybrid models that combine mechanistic biological knowledge and deep learning to guarantee interpretability as well as accuracy.[74]

Conventional narrow guidelines are being developed to exchanged with adaptive procedures, N of 1 designs, and virtual control cores manufactured utilizing genuine world data. Gimmicks like I-SPY, WINTHER and my Pathway demonstrate how AI and dynamic endpoints like ctDNA kinetics can revise the regime of regulation and therapy.[75]

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

Among the most game-changing innovations under development, there will be the usage of digital twins, or the virtual multi-omic images of individual patients, which allow mimicking the response to treatment, toxicity, and resistance development rates. Such digital avatars will be able to extend clinical decision-making well beyond the capabilities of humans. It is also important to note that making those technologies inclusive and accessible worldwide is a crucial step. The federated learning enables AI models to be trained with a diversity of decentralized authorized data sets with privacy maintained. Precision oncology can be made ubiquitous with the help of mobile genomic platforms and open-access decision tools, and in underserved areas of the world.

III. CONCLUSION

In order to achieve the full potential of anticipatory and evolution-aware oncology, the complementary elements should be integrated. Optimized pharmacogenomics-based therapies precondition the specific requirements that the therapeutic intervention not only be applicable to the tumor genomic signature but to also be harmonized to the metabolic and genetic individual profile as well, in order to have maximum efficacy and minimum adverse effects. Applied drug cases put the theoretical constructions into perspective and show that the practical significance of precision management in resistance treatment and clinical results is precisely measured.

By continuing to broaden the therapeutic implications of genomic intelligence it is possible to project personalized strategies beyond traditional tumor type and across disease stages to the immunogenomic combo and synthetic lethality and tumor microenvironment modulation. Moreover, the integration of pharmacovigilance and drug resistance surveillance into the precision workflow will reinforce the chain of reactions between the therapeutic approach and stewardship, so that new adverse drug reactions and resistance profiles become rapidly countered.

Collectively, these elements develop a comprehensive self-learning ecosystem of precision oncology the treatment of which is not fixed but dynamically optimized; tools and drugs of choice are not only reactive but are preemptively activated by real-time molecular understanding. This type of system will create resilience in the face of therapeutic failure and improve patient safety and it will open the gates to equitable, replicable innovation in cancer care.

ACKNOWLEDGEMENT

The authors sincerely thank the management and faculty of Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Bangalore, for their continuous support and encouragement throughout the preparation of this manuscript. We also extend our gratitude to Hassan Institute of Medical Sciences, Hassan, for their valuable guidance and academic support.

REFERENCES

[1]. Ottaiano A, Ianniello M, Santorsola M, Ruggiero R, Sirica R, Sabbatino F, Perri F, Cascella M, Di Marzo M, Berretta M, Caraglia M. From chaos to opportunity: decoding cancer heterogeneity for enhanced treatment strategies. Biology. 2023 Aug 29;12(9):1183.

[2]. Liang YH. *Pan-Cancer Universal Targets for Immunotherapy Resulted From Transposable Elements Activation* (Doctoral dissertation, Washington University in St. Louis).

[3]. Pratiwi L, Mashudi FH, Ningtyas MC, Sutanto H, Romadhon PZ. Genetic profiling of acute and chronic leukemia via next-generation sequencing: current insights and future perspectives. Hematology Reports. 2025 Mar 28;17(2):18.

[4]. Chambial P, Bhukya PL, Bahl V, Thakur N. Conventional methods of cancer therapy. InNanoparticles in Cancer Theranostics 2024 Oct 7 (pp. 173-195). CRC Press.

[5]. Mani DR, Krug K, Zhang B, Satpathy S, Clauser KR, Ding L, Ellis M, Gillette MA, Carr SA. Cancer proteogenomics: current impact and future prospects. Nature Reviews Cancer. 2022 May;22(5):298-313.

[6]. Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nature Reviews Cancer. 2020 Dec;20(12):743-56.

[7]. Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, Albalawi IA, Masoodi T, Subbaraj GK, Jamal F, Singh M. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer and Metastasis Reviews. 2024 Mar;43(1):197-228.

[8]. Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome medicine. 2020 Jan 14;12(1):8.

[9]. Adekola P. Multi-Scale Modeling in Cancer Systems Biology: Linking Transcriptomic Landscapes to Clinical Decision-Making.

[10]. Ali H. Artificial intelligence in multi-omics data integration: Advancing precision medicine, biomarker discovery and genomic-driven disease interventions. Int J Sci Res Arch. 2023;8(1):1012-30.

[11]. Raval H, Bhattacharya S. Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy. Current Cancer Drug Targets. 2025 Jun;25(6):586-619.

[12]. Mao Y, Shangguan D, Huang Q, Xiao L, Cao D, Zhou H, Wang YK. Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges. Molecular Cancer. 2025 Apr 23;24(1):123.

[13]. Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW. Acquired resistance in cancer: towards targeted therapeutic strategies. Nature Reviews Cancer. 2025 Jun 3:1-21.

[14]. Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nature reviews Drug discovery. 2020 Jan;19(1):39-56.

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

[15]. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. Journal of hematology & oncology. 2022 Sep 12;15(1):131.
[16]. Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C, Staaf J, Ploeger C, Lassen U, Le Tourneau C, Lehtiö J. Precision cancer medicine: Concepts, current practice, and future developments. Journal of internal medicine. 2023 Oct;294(4):455-81.
[17]. Athanasopoulou K, Michalopoulou VI, Scorilas A, Adamopoulos PG. Integrating Artificial Intelligence in Next-Generation Sequencing: Advances, Challenges, and Future Directions. Current Issues in Molecular Biology. 2025 Jun 19;47(6):470.
[18]. Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita N, McLaren K, Starkey M, Ward S, Wilding J, Ahmed M, Argasinska J. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic acids research. 2024 Jan 5;52(D1):D1210-7.
[19]. Nussinov R, Jang H, Tsai CJ, Cheng F. Precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers. PLoS computational biology. 2019 Mar 28;15(3):e1006658.
[20]. Abdi G, Tarighat MA, Jain M, Tendulkar R, Tendulkar M, Barwant M. Revolutionizing genomics: exploring the potential of next-generation sequencing. InAdvances in Bioinformatics 2024 Feb 6 (pp. 1-33). Singapore: Springer Nature Singapore.
[21]. Srivastava U, Kanchan S, Kesheri M, Gupta MK, Singh S. Types of omics data: genomics, metagenomics, epigenomics, transcriptomics, proteomics, metabolomics, and phenomics. InIntegrative Omics 2024 Jan 1 (pp. 13-34). Academic Press.
[22]. Paulson D, Johnson A. Integrating Artificial Intelligence with Genomic and Biomarker Data for the Advancement of Personalized Therapeutics in a Human-Centric Framework.
[23]. Nass SJ, Patlak M, Zevon E, editors. Improving cancer diagnosis and care: clinical application of computational methods in precision oncology: proceedings of a workshop.
[24]. Tsimberidou AM, Kahle M, Vo HH, Baysal MA, Johnson A, Meric-Bernstam F. Molecular tumour boards—current and future considerations for precision oncology. Nature Reviews Clinical Oncology. 2023 Dec;20(12):843-63.
[25]. Gupta S, Kumar D, Negi R, Singh R, Ansari MJ, Kashyap S, Mehrotra S, editors. Genomic intelligence: metagenomics and artificial intelligence. CRC Press; 2024 Dec 6.
[26]. Craig M, Jenner AL, Namgung B, Lee LP, Goldman A. Engineering in medicine to address the challenge of cancer drug resistance: from micro-and nanotechnologies to computational and mathematical modeling. Chemical Reviews. 2020 Nov 5;121(6):3352-89.
[27]. Chaux A. Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic Horizons.
[28]. Stubbs NM, Roady TJ, Schwermann MP, Eteshola EO, MacDonald WJ, Purcell C, Ryspayeva D, Verovkina N, Tajiknia V, Ghandali M, Voong V. Acquired resistance to molecularly targeted therapies for cancer. Cancer Drug Resistance. 2025 Jun 5;8:27.
[29]. Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Frontiers in immunology. 2021 May 27;12:656364.
[30]. Zhang Y, Wang W. Advances in tumor subclone formation and mechanisms of growth and invasion. Journal of Translational Medicine. 2025 Apr 21;23(1):461.
[31]. Huang Y. Towards New Approaches for Studying Personalized Gut Microbiota and Host-Microbe Interactions. Columbia University; 2022.
[32]. Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S. New insights into the role of EMT in tumor immune escape. Molecular oncology. 2017 Jul;11(7):824-46.
[33]. Adhit KK, Wanjari A, Menon S. Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine. Cureus. 2023 Dec 8;15(12).
[34]. Wang Z, Bai J, Jiang D, Li Y, Hu X, Efetov S, Cao Y, Kayaalp C, Dulskas A, Shaw D, Yang M. Liquid biopsy for monitoring minimal residual disease in colorectal cancer: a promising approach with clinical implications. Clinical Surgical Oncology. 2024 Sep 1;3(3):100056.
[35]. Chaux A. Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic Horizons.
[36]. Tiwari A, Mishra S, Kuo TR. Current AI technologies in cancer diagnostics and treatment. Molecular Cancer. 2025 Jun 2;24(1):159.
[37]. Fu SW, Tang C, Tan X, Srivastava S. Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma. Expert review of molecular diagnostics. 2024 Oct 2;24(10):937-55.
[38]. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Medical Oncology. 2022 Jun 15;39(8):120.
[39]. Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW. Acquired resistance in cancer: towards targeted therapeutic strategies. Nature Reviews Cancer. 2025 Jun 3:1-21.
[40]. Rituraj, Pal RS, Wahlang J, Pal Y, Chaitanya MV, Saxena S. Precision oncology: transforming cancer care through personalized medicine. Medical Oncology. 2025 Jun 9;42(7):246.
[41]. Bhamidipaty V, Bhamidipaty DL, Bhamidipaty KD, Botchu R. Intelligent health care: applications of artificial intelligence and machine learning in computational medicine. InBlockchain and Digital Twin for Smart Hospitals 2025 Jan 1 (pp. 133-169). Elsevier.

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

[42]. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates. 2007 Jun 1;10(3):81-100.

[43]. Liu S, Jiang A, Tang F, Duan M, Li B. Drug-induced tolerant persisters in tumor: Mechanism, vulnerability and perspective implication for clinical treatment. Molecular Cancer. 2025 May 24;24(1):150.

[44]. Ravi R, Kesari HV. Novel study designs in precision medicine–basket, umbrella and platform trials. Current Reviews in Clinical and Experimental Pharmacology Formerly Current Clinical Pharmacology. 2022 Jul 1;17(2):114-21.

[45]. Cheng H. 2021 Prostate Cancer Clinical Consortium Clinical Research Site: University of Washington.

[46]. Freeman JW. Structural biology of the tumor microenvironment. InTumor Microenvironment: Cellular, Metabolic and Immunologic Interactions 2021 Dec 10 (pp. 91-100). Cham: Springer International Publishing.

[47]. Massa C, Wang Y, Marr N, Seliger B. Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway. International journal of molecular sciences. 2023 Apr 4;24(7):6736.

[48]. Janeeh AS, Bajbouj K, Rah B, Abu-Gharbieh E, Hamad M. Interplay between tumor cells and immune cells of the colorectal cancer tumor microenvironment: Wnt/β-catenin pathway. Frontiers in Immunology. 2025 Jun 18;16:1587950.

[49]. Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal transduction and targeted therapy. 2020 Oct 30;5(1):249.

[50]. Delahaye C, Figarol S, Pradines A, Favre G, Mazieres J, Calvayrac O. Early steps of resistance to targeted therapies in non-small-cell lung cancer. Cancers. 2022 May 25;14(11):2613.

[51]. Blanco-Heredia J, Souza CA, Trincado JL, Gonzalez-Cao M, Gonçalves-Ribeiro S, Gil SR, Pravdyvets D, Cedeño S, Callari M, Marra A, Gazzo AM. Converging and evolving immuno-genomic routes toward immune escape in breast cancer. Nature communications. 2024 Feb 21;15(1):1302.

[52]. Hesser LA. *The Development of a Synbiotic Butyrate-Producing Bacterial Therapeutic for Food Allergy* (Doctoral dissertation, The University of Chicago).

[53]. Sánchez-Bayona R, Catalán C, Cobos MA, Bergamino M. Pharmacogenomics in solid tumors: a comprehensive review of genetic variability and its clinical implications. Cancers. 2025 Mar 7;17(6):913.

[54]. Narendra G, Choudhary S, Raju B, Verma H, Silakari O. Role of genetic polymorphisms in drug-metabolizing enzyme-mediated toxicity and pharmacokinetic resistance to anti-cancer agents: a review on the pharmacogenomics aspect. Clinical Pharmacokinetics. 2022 Nov;61(11):1495-517.

[55]. Singh JP, Gaur V, Dubey P. Precision, Prediction and Progress: A New Era in Pharmacology. International Journal of Innovative Science and Research Technology. 2025 Apr 22;10(4):888-910.

[56]. Ji J, Wang C, Fakih M. Rechallenge with BRAF and anti-EGFR inhibitors in patients with metastatic colorectal cancer harboring BRAFV600E mutation who progressed on cetuximab and encorafenib with or without binimetinib: a case series. Clinical Colorectal Cancer. 2022 Sep 1;21(3):267-71.

[57]. Abbotts R, Dellomo AJ, Rassool FV. Pharmacologic induction of BRCAness in BRCA-proficient cancers: expanding PARP inhibitor use. Cancers. 2022 May 26;14(11):2640.

[58]. Gatenby RA, Brown JS. The evolution and ecology of resistance in cancer therapy. Cold Spring Harbor perspectives in medicine. 2020 Nov 1;10(11):a040972.

[59]. Desai A, Vázquez TA, Arce KM, Corassa M, Mack PC, Gray JE, Pellini B. ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer. Cancers. 2024 Feb 26;16(5):940.

[60]. Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M. Use of ctDNA in early breast cancer: analytical validity and clinical potential. NPJ Breast Cancer. 2024 Jun 19;10(1):50.

[61]. Mezei T, Kolcsár M, Joó A, Gurzu S. Image analysis in histopathology and cytopathology: from early days to current perspectives. Journal of Imaging. 2024 Oct 14;10(10):252.

[62]. Suura SR. Integrating Artificial Intelligence, Machine Learning, and Big Data with Genetic Testing and Genomic Medicine to Enable Earlier, Personalized Health Interventions. Deep Science Publishing; 2025 Apr 13.

[63]. Ross E. *Inferring tumour evolution from single-cell and multi-sample data* (Doctoral dissertation).

[64]. Romano C, Di Benedetto MD, Borri A. Stackelberg Evolutionary Games With Modulated Leadership: A Three-Agent Framework for Tumor-Immune Dynamics. IEEE Control Systems Letters. 2025 May 26.

[65]. Komi LS, Mustapha AY, Forkuo AY, Osamika D. Reviewing Pharmacovigilance Strategies Using Real-World Data for Drug Safety Monitoring and Management.

[66]. Du H, Wang J, Wang Z. Cardiovascular adverse effects of immunotherapy in cancer: insights and implications. Frontiers in Oncology. 2025 Jun 18;15:1601808.

[67]. Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, Fleitas T, Roda D, Cervantes A. Personalized medicine: recent progress in cancer therapy. Cancers. 2020 Apr 19;12(4):1009.

[68]. Subbiah V, Baik C, Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends in cancer. 2020 Sep 1;6(9):797-810.

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/25aug886

[69]. El-Heliebi A. for the Analysis of Cell-Free Circulating DNA. Nucleic Acid Nanotheranostics: Biomedical Applications. 2019 Feb 26:133**.**

[70]. Pourmir I. *Membrane and soluble forms of the immune checkpoint TIM-3 in clear cell renal cell carcinoma: a promising biomarker for cancer immunotherapy* (Doctoral dissertation, Université Paris Cité).

[71]. Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduction and Targeted Therapy. 2020 Oct 19;5(1):241.

[72]. Liu H. Angiotensin system inhibition in pancreatic ductal adenocarcinoma. Harvard University; 2017.

[73]. Zhao S, Zhu A, Mozannar H, Sontag D, Talwalkar A, Chen V. Codinggenie: A proactive llm-powered programming assistant. arXiv preprint arXiv:2503.14724. 2025 Mar 18.

[74]. Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ precision oncology. 2020 Jun 15;4(1):19.

[75]. Bronkhorst AJ, Holdenrieder S. The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization. Medizinische Genetik. 2023 Nov 29;35(4):201-35.